Department of Hematology, Huanggang Central Hospital, China.
Department of Medical Care Security, Huanggang Central Hospital, China.
Adv Clin Exp Med. 2023 May;32(5):523-532. doi: 10.17219/acem/156346.
One of the most significant advancements in nursing technology for cancer patients has been the development of implantable port catheters and peripherally inserted central venous catheters. They create an essential, dependable route for subjects to receive chemotherapy, long-term infusions and nutritional care, and provide a site for regular blood draws.
We performed a meta-analysis to evaluate the complications of implanted port catheters and peripherally inserted central catheters in chemotherapy-treated cancer patients.
A systematic literature search up to April 2022 was performed and a total of 11,801 articles have been retrieved. Of these, 5017 concerned peripherally inserted central catheters and 6784 implanted port catheters to administer chemotherapy. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (95% CIs) were calculated to assess the complications of implanted port catheters and peripherally inserted central catheters in chemotherapy-treated cancer patients using dichotomous and contentious methods with randomor fixed-effects models.
Peripherally inserted central catheters had significantly higher incidence of occlusion complications (OR: 5.43, 95% CI: 3.46-8.52, p < 0.001), longer durations of local infection (OR: 2.94, 95% CI: 2.17-4.00, p < 0.001), higher incidence of catheter-related infection (OR: 2.13, 95% CI: 1.19-3.83, p = 0.01), higher rate of malposition (OR: 6.46, 95% CI: 2.93-14.27, p < 0.001), higher rates of catheter-related thrombosis (OR: 2.71, 95% CI: 1.90-3.87, p < 0.001), higher incidence of phlebitis complications (OR: 6.67, 95% CI: 2.94-15.11, p < 0.001), higher incidence of accidental removal (OR: 3.38, 95% CI: 1.97-5.81, p < 0.001), and a shorter catheter lifespan (MD: -233.16, 95% CI: -449.52--16.80, p = 0.03) in subjects undergoing chemotherapy compared to those in whom implanted port catheters were used.
Implantable port catheter has advantages over peripherally inserted central catheter in decreasing cancer patients' complications. The outcomes provide evidence for practitioners to select which type of central venous catheters is better for cancer chemotherapy subject.
癌症患者护理技术的最重要进展之一是开发植入式港港置管和外周静脉置入中心静脉导管。它们为患者提供了接受化疗、长期输注和营养支持的必要且可靠的途径，并为定期采血提供了部位。
我们进行了一项荟萃分析，以评估植入式港港置管和外周静脉置入中心静脉导管在化疗治疗癌症患者中的并发症。
系统检索截至 2022 年 4 月的文献，共检索到 11801 篇文章。其中，5017 篇涉及外周静脉置入中心静脉导管，6784 篇涉及植入式港港置管以进行化疗。使用二分类和连续变量方法，采用随机或固定效应模型计算优势比（OR）和均数差（MD）及其 95%置信区间（95%CI），以评估植入式港港置管和外周静脉置入中心静脉导管在化疗治疗癌症患者中的并发症。
与植入式港港置管相比，外周静脉置入中心静脉导管的闭塞并发症发生率更高（OR：5.43，95%CI：3.46-8.52，p<0.001），局部感染持续时间更长（OR：2.94，95%CI：2.17-4.00，p<0.001），导管相关性感染发生率更高（OR：2.13，95%CI：1.19-3.83，p=0.01），位置不当发生率更高（OR：6.46，95%CI：2.93-14.27，p<0.001），导管相关性血栓形成发生率更高（OR：2.71，95%CI：1.90-3.87，p<0.001），静脉炎并发症发生率更高（OR：6.67，95%CI：2.94-15.11，p<0.001），意外拔管发生率更高（OR：3.38，95%CI：1.97-5.81，p<0.001），导管使用寿命更短（MD：-233.16，95%CI：-449.52--16.80，p=0.03）。
与外周静脉置入中心静脉导管相比，植入式港港置管在降低癌症患者并发症方面具有优势。这些结果为临床医生选择哪种类型的中心静脉导管更适合癌症化疗患者提供了证据。
